News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Panel Once Again Rejects Wider Use Of Johnson & Johnson (JNJ) Drug



1/17/2014 6:52:00 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

The FDA’s Cardiovascular and Renal Drugs Advisory Committee once again turned down the supplemental new drug application for an acute coronary syndrome indication for Johnson & Johnson’s Xarelto (rivaroxaban). The nearly unanimous vote (10-0, with 1 abstention) was in line with a highly negative review from FDA staff members. Although originally the subject of high praise when it first came out, the pivotal ATLAS ACS 2-TIMI 51 trial has been bedeviled by criticism since the FDA drew attention to the unusually large amount of missing trial data.

Help employers find you! Check out all the jobs and post your resume.

Read at Forbes
Read at ABC News
Read at Bloomberg
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES